Does H2-receptor antagonist alter the renal function of cyclosporine-treated kidney grafts?
Histamine-type 2 antagonists (H2-blockers) as represented by cimetidine have been shown to adversely affect renal allograft function, particularly when coadministered with cyclosporine, currently a major immunosuppressant. To determine whether or not a newer and more powerful H2-blocker, famotidine, would produce similar adverse effects, we assessed seven cyclosporine-treated renal allograft recipients with regard to changes in their renal function on or off the H2-blocker over a one-week period. Neither the administration nor withdrawal of famotidine (20-40 mg/day) resulted in any significant changes in serum creatine, BUN, urine output or cyclosporine trough levels, suggesting that famotidine can be safely administered as an H2-blocker to cyclosporine-treated renal allograft recipients.
Inoue
S
S
Department of Organ Transplantation, University of Tokyo, Japan.
Sugimoto
H
H
Nagao
T
T
Akiyama
N
N
D000328:Adult; D001806:Blood Urea Nitrogen; D003404:Creatinine / Q000097:blood; D003524:Cyclosporins / Q000097:blood*; D015738:Famotidine / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006084:Graft Rejection; D006801:Humans; D007668:Kidney / Q000187:drug effects* / Q000502:physiology; D016030:Kidney Transplantation / Q000502:physiology*; D008875:Middle Aged
D003524:Cyclosporins; D015738:Famotidine; D003404:Creatinine